These studies and trials have led to a shift in our understanding of IL-2 from a cytokine known for the activation of effector T cells against cancer when used at a high dose, to a cytokine that activates Treg cells to control autoimmunity at a low dose. This evidence concerns the gene IL2 and cancer.